-
Something wrong with this record ?
The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project
R. Ceska, G. Latkovskis, MV. Ezhov, T. Freiberger, K. Lalic, O. Mitchenko, G. Paragh, Z. Petrulioniene, B. Pojskic, K. Raslova, AB. Shek, B. Vohnout, T. Altschmiedova, V. Todorovova,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Anticholesteremic Agents therapeutic use MeSH
- Antibodies, Monoclonal, Humanized therapeutic use MeSH
- Hyperlipoproteinemia Type II diagnosis drug therapy epidemiology MeSH
- Incidence MeSH
- Humans MeSH
- International Cooperation * MeSH
- PCSK9 Inhibitors MeSH
- Mass Screening methods MeSH
- Delivery of Health Care standards MeSH
- Proprotein Convertase 9 immunology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Geographicals
- Europe MeSH
PURPOSE OF REVIEW: Familial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With "central support," more centers and countries participated in the project. Subsequently, individual countries reported the results at the beginning and end of the project. Collected data were statistically evaluated. RECENT FINDINGS: The increasing number of patients in databases, from 7500 in 2014 to 25,347 in 2018, demonstrates the improvement in overall effectiveness, as well as an increase in the number of centers from 70 to 252. Before all, LDL-C decreased by 41.5% and total cholesterol by 32.3%. As data from all countries and patients were not available at the time of the analysis, only those results from 10 countries and 5585 patients at the beginning of the project and at the time of writing are included. Our data are quite positive. However, our results have only limited validity. Our patients are far from the target levels of LDL-C. The situation can be improved with the introduction of new therapy, PCSK9-i, evolocumab, and alirocumab. International cooperation improved the screening of FH and finally led to an improvement in cardiovascular risk.
Cantonal Hospital Zenica Zenica Bosnia and Herzegovina
Coordination Center for Familial Hyperlipidemias Slovak Medical University Bratislava Slovakia
Department of Internal Medicine Faculty of Medicine University of Debrecen Debrecen Hungary
National Cardiology Research Center Moscow Russia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023882
- 003
- CZ-PrNML
- 005
- 20201214131543.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11883-019-0797-3 $2 doi
- 035 __
- $a (PubMed)31230174
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ceska, Richard $u Third Department of Medicine - Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. richard.ceska@vfn.cz.
- 245 14
- $a The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project / $c R. Ceska, G. Latkovskis, MV. Ezhov, T. Freiberger, K. Lalic, O. Mitchenko, G. Paragh, Z. Petrulioniene, B. Pojskic, K. Raslova, AB. Shek, B. Vohnout, T. Altschmiedova, V. Todorovova,
- 520 9_
- $a PURPOSE OF REVIEW: Familial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With "central support," more centers and countries participated in the project. Subsequently, individual countries reported the results at the beginning and end of the project. Collected data were statistically evaluated. RECENT FINDINGS: The increasing number of patients in databases, from 7500 in 2014 to 25,347 in 2018, demonstrates the improvement in overall effectiveness, as well as an increase in the number of centers from 70 to 252. Before all, LDL-C decreased by 41.5% and total cholesterol by 32.3%. As data from all countries and patients were not available at the time of the analysis, only those results from 10 countries and 5585 patients at the beginning of the project and at the time of writing are included. Our data are quite positive. However, our results have only limited validity. Our patients are far from the target levels of LDL-C. The situation can be improved with the introduction of new therapy, PCSK9-i, evolocumab, and alirocumab. International cooperation improved the screening of FH and finally led to an improvement in cardiovascular risk.
- 650 _2
- $a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
- 650 _2
- $a anticholesteremika $x terapeutické užití $7 D000924
- 650 _2
- $a poskytování zdravotní péče $x normy $7 D003695
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperlipoproteinemie typ II $x diagnóza $x farmakoterapie $x epidemiologie $7 D006938
- 650 _2
- $a incidence $7 D015994
- 650 12
- $a mezinárodní spolupráce $7 D007391
- 650 _2
- $a plošný screening $x metody $7 D008403
- 650 _2
- $a proproteinkonvertasa subtilisin/kexin typu 9 $x imunologie $7 D000071449
- 650 _2
- $a PCSK9 inhibitory $7 D000091362
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Latkovskis, Gustavs $u Latvian Research Institute of Cardiology, Faculty of Medicine, University of Latvia, Riga, Latvia. Paul Stradins Clinical University Hospital, Riga, Latvia.
- 700 1_
- $a Ezhov, Marat V $u National Cardiology Research Center, Moscow, Russia.
- 700 1_
- $a Freiberger, Tomas $u Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic. Medical Faculty, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Lalic, Katarina $u Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade, Serbia. Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
- 700 1_
- $a Mitchenko, Olena $u National Registry Coordinator in Ukraine, Kiev, Ukraine.
- 700 1_
- $a Paragh, Gyorgy $u Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- 700 1_
- $a Petrulioniene, Zaneta $u Vilnius University Faculty of Medicine, Vilnius, Lithuania. Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
- 700 1_
- $a Pojskic, Belma $u Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina.
- 700 1_
- $a Raslova, Katarina $u Coordination Center for Familial Hyperlipidemias, Slovak Medical University, Bratislava, Slovakia.
- 700 1_
- $a Shek, Aleksandr B $u Head of Department of Ischemic Heart Disease and Atherosclerosis, Republican Specialised Center of Cardiology, Tashkent, Uzbekistan.
- 700 1_
- $a Vohnout, Branislav $u Institute of Nutrition, Faculty of Nursing and Health Professional Studies and Coordination Centre for Familial Hyperlipoproteinemias, Slovak Medical University in Bratislava, Bratislava, Slovakia. Institute of Epidemiology, School of Medicine, Comenius University, Bratislava, Slovakia.
- 700 1_
- $a Altschmiedova, Tereza $u Third Department of Medicine - Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Todorovova, Veronika $u Third Department of Medicine - Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 773 0_
- $w MED00186151 $t Current atherosclerosis reports $x 1534-6242 $g Roč. 21, č. 9 (2019), s. 36
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31230174 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214131541 $b ABA008
- 999 __
- $a ok $b bmc $g 1596201 $s 1114558
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 21 $c 9 $d 36 $e 20190622 $i 1534-6242 $m Current atherosclerosis reports $n Curr Atheroscler Rep $x MED00186151
- LZP __
- $a Pubmed-20201125